Journal & Media Articles

Videos

HIPEC Consensus Statement

In October 2006, a consensus statement from the Peritoneal Surface Malignancy Group (PSMG), a group of 72 leading national and international surgical oncologists from 55 cancer centers in 14 countries, including the United States, was published in the Annals of Surgical Oncology. The group concluded that surgery followed by heated chemotherapy delivered through the lower abdomen of the patient, may significantly increase the life expectancy for patients with Stage IV colorectal cancer. Click here to view the HIPEC Consensus Statement.

Print Media Articles

New Cancer Treatment Helping Some Live Longer (from the The Boston Channel, January, 2008)

Surgery for Peritoneal Carcinomatosis: Right for You? (from the Colorectal Cancer Coalition, Spring, 2007)

Heated Chemotherapy Boosts Survival (from CancerFacts.com, Nov. 3, 2006)

Report Calls For Using Heated Chemotherapy After Colon Cancer Surgery To Optimize Patient Survival (from Science Daily, Nov. 6, 2006)

Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) (from the University of Louisville, 2003)

To view the abstracts, simply click on the text of the abstract you'd like to view. The typical underlining of links has been omitted to make the text easier to read.

Click here for abstracts specific to Colorectal Cancer

Click here for abstracts specific to Ovarian Cancer

2008 Abstracts

"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

[Peritoneal mesothelioma: Long survival with intraperitoneal chemotherapy, lanreotide and mucolytics.]

Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

HIPEC: The Complexities of Clinical Trials.

Intraperitoneal chemotherapy in ovarian cancer: an update

First surgical tumour reduction of peritoneal surface malignancy in a rat's model.

Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Peritoneal carcinomatosis from colorectal cancer: HIPEC?

Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with Paclitaxel: a clinical and pharmacokinetic study.

[Treatment of peritoneal carcinomatosis with surgery and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC): new aspects and validated indications]

Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intra-peritoneal-chemotherapy: A single western center experience.

Reported Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity.

Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin.

Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.

Pharmacokinetics of heated intraperitoneal oxaliplatin.

Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.

Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis.

Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.

Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin.

Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.

Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.

Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs.

Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer.

Interstitial pneumonitis: an exceptional toxicity of hyperthermic intraperitoneal mitomycin C.

2007 Abstracts

[Updated treatment of peritoneal carcinomas: a review]

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis

[Peritoneal carcinomatosis. Ten years of applying the new combined triple therapy. Personal experience.]

Treatment of peritoneal carcinomatosis from colorectal cancer with cytoreductive surgery and perioperative intraperitoneal chemotherapy: state of the art and future prospects.

[Preliminary results for intraperitoneal chemotherapy in abdominal cancers]

[Systemic treatment of peritoneal metastases]

[Peritoneal carcinomatosis : Surgical treatment, including hyperthermal intraperitoneal chemotherapy.]

Feasibility study of postoperative intraperitoneal hyperthermochemotherapy by radiofrequency capacitive heating system for advanced gastric cancer with peritoneal seeding.

Investigations on permeation of mitomycin C through double layers of natural rubber gloves.

[New treatment of peritoneal carcinomatosis from colorectal cancer. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy]

Incidence of Postoperative Pancreatic Fistula and Hyperamylasemia after Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy

Hyperthermic intraperitoneal chemoperfusion is an option for treatment of peritoneal carcinomatosis in children.

Thermal sensitization through ROS modulation: a strategy to improve the efficacy of hyperthermic intraperitoneal chemotherapy.

Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings.

Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis.

Laboratory and clinical basis for hyperthermia as a component of intrcavitary chemotherapy

Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).

[Application of hyperthermic intraoperative intraperitoneal chemotherapy in patients with gastric cancer]

A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer.

A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats.

Where does cytoreductive surgery and hyperthermic intraperitoneal chemotherapy fit into the "usual care" of patients with carcinomatosis?

Detection and treatment of recurrent disease after cytoreduction and HIPEC.

Morbidity and quality of life following cytoreduction and HIPEC.

Cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis of ovarian cancer.

Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma.

Clinical results of cytoreduction and HIPEC in pseudomyxoma peritonei.

HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.

Results of cytoreduction followed by HIPEC in carcinomatosis of colorectal origin.

Pharmacodynamic aspects of intraperitoneal cytotoxic therapy.

Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients.

Does intraperitoneal therapy have a role in recurrent ovarian cancer?

Cytoreductive surgery for peritoneal malignancies-development of standards of care for the community.

Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.

Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.

Hemodynamic and cardiovascular problems during modified hyperthermic intraperitoneal perioperative chemotherapy.

Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Technology for the delivery of hyperthermic intraoperative intraperitoneal chemotherapy: a survey of techniques.

Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma.

Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer.

Combination of intraperitoneal hyperthermic perfusion chemotherapy (IHPC) with intraperitoneal chemotherapy as a treatment modality for persisten ovarian cancer.

Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.

Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies.

Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei.

Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases.

Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC).

Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.

[Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy]

[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia]

Cytoreduction and intraperitoneal chemotherapy for the treatmentment of endometrial carcinoma recurrent within the peritoneal cavity.

Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model.

Paclitaxel/beta-cyclodextrin complexes for hyperthermic peritoneal perfusion - formulation and stability.

Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell deth in vitro.

Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.

A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.

Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin.

Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome.

Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan.

A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Cyclooxygenase inhibition and hyperthermia for the potentation of the cytotoxic response in ovarian cancer cells

2006 Abstracts

Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery for peritoneal carcinomatosis of colorectal origin: a novel treatment strategy with promising results in selected patients.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C.

Adjuvant hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) associated with curative surgery for locally advanced gastric carcinoma. An initial experience.

Hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis of digestive and peritoneal origin: rationale.

Cytoreduction and HIPEC for peritoneal carcinomatosis from colorectal origin: the Amsterdam experience.

Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C.

Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy.

Peritoneal Surface Oncology: A progress report.

Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.

Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.

Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.

Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.

Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures.

Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.

2005 Abstracts

Use of hyperthermic intraperitoneal chemotherapy (HIPEC) in management of peritoneal carcinomatosis from colorectal origin.

Cytoreductive surgery and intraoperative intraperitoneal hyperthermic chemotherapy in patients with peritoneal carcinomatosis of colorectal origin.

Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion.

Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion.

Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions.

Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: an experimental study.

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma.

Treatment of peritoneal surface malignancy by peritonectomy and intraperitoneal chemotherapy: a novel therapy with curative potential!

A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis.

Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study.

Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma.

Long-term survival of peritoneal carcinomatosis of colorectal origin.

[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal colorectal carcinomatosis: a newly validated standard whose contribution remains to be assessed]

Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.

Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: a long-term follow-up.

2004 Abstracts

Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer

Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.

Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer.

Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients.

Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei.

Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion.

Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome.

Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.

Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.

Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer.

2003 Abstracts

Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.

[Resectional treatment of peritoneal carcinomatosis followed by intraperitoneal chemotherapy, practical aspects]

Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP).

[A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion]

Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality.

Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis.

Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents.

Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures.

Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities.

Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin.

Hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from gastric adenocarcinoma.

[Peritoneal mesothelioma: results of a complicated and aggressive procedure incorporating peritonectomy and intraperitoneal hyperthermic chemotherapy, and prospects derived from bench-to-bedside research]

[Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei]

[Treatment of pseudomyxoma peritonei using cytoreduction and intraperitoneal hyperthermic chemotherapy]

[Treatment of peritoneal mesothelioma using cytoreduction and intraperitoneal hyperthermic chemotherapy]

Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.

Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).

Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy.

Hyperthermia in gynecologic cancers.

Computed tomographic features of peritoneal carcinomatosis treated by intraperitoneal chemohyperthermia.

Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma.

Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.

[Intraperitoneal hyperthermic perfusion chemotherapy in recurrent ovarian cancer]

Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.

Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.

Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.

2002 Abstracts

Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.

Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei.

Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion.

Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy.

Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.

Continuous Intraoperative Intraperitoneal Hyperthermic Chemoperfusion (CIIPHCP) in the treatment of advanced stage and recurrent granulosa cell tumors. Report of two cases.

Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.

[Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis]

Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.

Long-term survival of a patient with primary papillary serous carcinoma of the peritoneum treated by subtotal peritonectomy plus intraoperative chemohyperthermia.

[Primary peritoneal tumors: report on a series of eight cases and review of the literature]

Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.

Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C.

Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.

Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma.

Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C.

2001 Abstracts

Malignant peritoneal mesothelioma.

Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy.

A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP).

Palliation with a glimmer of hope: management of resectable gastric cancer with peritoneal carcinomatosis.

[Intraperitoneal chemo-hyperthermia with "overflow" open abdomen]

Intraperitoneal chemohyperthermia: rationale, technique, indications, and results.

Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study.

Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer.

Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.

Hyperthermia and hypoxia: new developments in anticancer chemotherapy.

Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma.

[Multiorgan resection in combination with intraoperative, hyperthermic chemotherapy in recurrent fibrolamellar hepatocellular carcinoma. An individual therapeutic concept for a 21-year-old patient]

Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.

Effect of mild whole body hyperthermia on cytotoxic action of N-methyl-N'-nitro-N-nitrosoguanidine in Swiss mice.

Multimodal treatment of peritoneal carcinomatosis and sarcomatosis.

Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.

Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis.

2000 Abstracts

Research trends in the treatment of colorectal cancer.

Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection.

Sensitivity of human pancreatic adenocarcinoma tumor lines to chemotherapy, radiotherapy, and hyperthermia.

Regulatory effects of fever-range whole-body hyperthermia on the LPS-induced acute inflammatory response.

Intraperitoneal chemohyperthermia for peritoneal carcinomatosis: original modeling, clinical tolerance and results study about 30 patients.

Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.

[Peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemohyperthermia]

[Complications and tolerance of heated intraperitoneal chemotherapy and cytoreductive surgery for peritoneal carcinomatosis: results of a phase I-II study of peritoneal carcinomatosis from different sources]

De bree, witkamp AJ, zoetmulder FAN. Peroperative hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer.

Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer.

Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis.

Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis.

Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancer.

Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer.

An evaluation of l-ephedrine neurotoxicity with respect to hyperthermia and caudate/putamen microdialysate levels of ephedrine, dopamine, serotonin, and glutamate.

1999 Abstracts

Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique.

[Treatment of gastric cancer]

[Treatment of peritoneal carcinomatosis using complete excision and intraperitoneal chemohyperthermia. A phase I-II study defining the best technical procedures]

[The effect of intra-abdominal temperature on the tissue and tumor diffusion of intraperitoneal cisplatin in a model of peritoneal carcinomatosis in rats]

[Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute]

Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP).

Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study.

Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies.

[Surgery associated with intraoperative hyperthermia-chemotherapy in the treatment of malignant tumors of the digestive system with peritoneal carcinosis]

Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis.

Treatment of primary peritoneal mesothelioma by hyperthemic intraperitoneal chemotherapy.

Peritoneal carcinomatosis: feature of dissemination. A review.

Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells.

Differential diagnosis of thyroid crisis and malignant hyperthermia in an anesthetized porcine model.

Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma.

[Hyperthermia in combination with chemotherapy in gynecological cancers]

A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.

1998 Abstracts

[New philosophy in the treatment of peritoneal carcinomatosis of gastrointestinal origin]

Pharmacokinetics of intraperitoneal gemcitabine in a rat model.

Continuous hyperthermic peritoneal perfusion for peritoneal dissemination of gastric cancer.

Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach.

[The role of intraperitoneal chemotherapy after curative excision of primary abdominopelvic sarcoma]

[Clinical result of intraperitoneal hyperthermic chemoperfusion for gastric cancer with serosal invasion to prevent peritoneal recurrence]

Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.

Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis.

Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.

Histologic evaluation of preventive measures for scald injury on the peritoneo-serosal surface due to intraoperative hyperthermic chemoperfusion for patients with gastric cancer and peritoneal metastasis.

Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model.

1997 Abstracts

[Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis]

Theoretical models for drug delivery to solid tumors.

[Study of the toxicity and results of intraperitoneal hyperthermic chemotherapy in 28 patients with peritoneal carcinomatosis]

Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery.

Clinical results of radiofrequency hyperthermia for malignant liver tumors.

Hyperthermia and verapamil inhibit the growth of human colon cancer xenografts in vivo through apoptosis.

Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.

[Peritoneal carcinosis treated by complete excision and immediate postoperative intra-peritoneal chemotherapy. Phase II study in 54 patients]

[Intraoperative (hyperthermic) intraperitoneal chemotherapy--considerations and aspects of safe intra- and postoperative treatment with cytostatic drugs]

Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells.

Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery.

Effect of lactic acid in tumours on antitumour activity of hyperthermia.

1996 Abstracts

Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Anaesthesia for intra-peritoneal perfusion of hyperthermic chemotherapy. Haemodynamic changes, oxygen consumption and delivery.

TNF-alpha and endotoxin serum levels in cancer patients undergoing intraperitoneal hyperthermic perfusion.

Complications of heated intraperitioneal chemotherapy and strategies for prevention.

Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion.

Peritoneal carcinomatosis and radioimmunoguided surgery.

Survival time and prevention of side effects of intraperitoneal hyperthermic perfusion with mitomycin C combined with surgery for patients with advanced gastric cancer.

Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C.

Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin.

Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis.

Colorectal cancer and peritoneal carcinomatosis.

Anti-tumor effects of hyperthermia plus granulocyte colony-stimulating factor.

Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases.

Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology.

Heat turn-over during hyperthermic peritoneal perfusion. An experimental study.

Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy.

2008 Colorectal Cancer Abstracts

2007 Colorectal Cancer Abstracts

2006 Colorectal Cancer Abstracts

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C.

Hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis of digestive and peritoneal origin: rationale.

Cytoreduction and HIPEC for peritoneal carcinomatosis from colorectal origin: the Amsterdam experience.

Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy.

Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

2005 Colorectal Cancer Abstracts

Use of hyperthermic intraperitoneal chemotherapy (HIPEC) in management of peritoneal carcinomatosis from colorectal origin.

Cytoreductive surgery and intraoperative intraperitoneal hyperthermic chemotherapy in patients with peritoneal carcinomatosis of colorectal origin.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C.

Long-term survival of peritoneal carcinomatosis of colorectal origin.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal colorectal carcinomatosis: a newly validated standard whose contribution remains to be assessed.

Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.

2004 Colorectal Cancer Abstracts

Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.

Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome.

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.

2003 Colorectal Cancer Abstracts

Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis.

Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities.

Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma.

Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.

2001 Colorectal Cancer Abstracts

Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.

Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis.

2008 Ovarian Cancer Abstracts

2007 Ovarian Cancer Abstracts

Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity.

2006 Ovarian Cancer Abstracts

Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.

2005 Ovarian Cancer Abstracts

Intraperitoneal hyperthermic chemotherapy in ovarian cancer.

Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: a long-term follow-up.

Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer.

Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer.

A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance.

Laboratory investigation of flow characteristics during intraperitoneal hyperthermic perfusion chemotherapy.

Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP).

A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion.

Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer.

Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.

Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer.

2003 Ovarian Cancer Abstracts

Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin.

Hyperthermia in gynecologic cancers.

Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.

2002 Ovarian Cancer Abstracts

Intraperitoneal hyperthermic perfusion chemotherapy in recurrent ovarian cancer.

2001 Ovarian Cancer Abstracts

Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study.